Integrins as target: first phase III trial launches, but questions remain.
Carter
Andrea
A
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017326:Clinical Trials, Phase III as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005909:Glioblastoma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D016023:Integrins / Q000187:drug effects* / Q000378:metabolism; D009369:Neoplasms / Q000139:chemically induced* / Q000188:drug therapy; D012910:Snake Venoms / Q000008:administration & dosage* / Q000009:adverse effects*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D016023:Integrins; D012910:Snake Venoms; C516631:volociximab; C422910:Cilengitide